Warfarin treatment and thrombolysis in acute stroke: Are the procrastinators right?

Neurology

Volumn 79, Issue 1, 2012, Pages 17-18

  Harrer, Judith U ^a,b   Seet, Raymond C S ^c  

^a Caritas Hospital Saarbrücken   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; DRUG SAFETY; EDITORIAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCORING SYSTEM; STROKE;

EID: 84863572024     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31825dceb8     Document Type: Editorial

References (10)

1. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999;53(suppl 4):S3-S14.
2. Saver JL, Gornbein J, Grotta J, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3-to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009; 40:2433-2437.
3. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2010;67:559-563.
4. Seet RC, Zhang Y, Moore SA, Wijdicks EF, Rabinstein AA. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011;42:2333-2335.
5. Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 2011;42:1041-1045.
6. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-2948.
7. Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 2012;79:31-38.
8. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med 2005;46:56-60.
9. Scott PA, Xu Z, Meurer WJ, et al. Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the Increasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke 2010;41:2026-2032.
10. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3-to 6-hour time window? Stroke 2006;37:2963-2969.